Non-alcoholic fatty liver disease (NAFLD) is mostly diagnosed in overweight and obese people. However, severe forms of NAFLD can also be detected in rare genetic diseases such as lipodystrophy or in patients with HIV, putting them at a high risk for developing liver failure, diabetes and cardiovascular diseases. Norbert Stefan and colleagues have now detected a yet unknown cause of NAFLD in lean…
Researchers from the University Hospital Zurich, ETH Zurich, Wyss Zurich and the University of Zurich have developed a machine that repairs injured human livers and keeps them alive outside the body for one week. This breakthrough may increase the number of available organs for transplantation, saving many lives of patients with severe liver diseases or cancer. Until now, livers could be stored…
A new effective treatment of hepatitis C that was made available to all Danes last year, not only combats the virus, but is also effective against potentially fatal complications such as reduced liver functioning and cirrhosis. This is the result of a new study from Aarhus University and Aarhus University Hospital. Hepatitis C is a serious disease, but the biggest threat to someone’s health is…
Non-alcoholic fatty liver disease (NAFLD) is becoming the most common chronic liver disorder in developed countries. Histological analysis of liver tissue is the only widely accepted test for diagnosing and distinguishing different stages of NAFLD. However, this technique provides only two-dimensional images of the liver tissue in low resolution and overlooks potentially important 3D structural…
Fatty liver disease is contributing to an increase in liver cancer and basic scientists at The University of Texas Health Science at Houston (UTHealth) have new insight as to why. In the journal Cancer Research, the investigators report that in mouse models, excess fat impairs the ability of a tumor-suppressing protein named HNF4α to do its job. “This study provides potential mechanisms for…
A pioneering European research project designed to develop new diagnostic tests to assess patients with Non-Alcoholic Fatty Liver Disease (NAFLD) has expanded giving access to more patients. Liver Investigation: Testing Marker Utility in Steatohepatitis (LITMUS) funded by the European Innovative Medicines Initiative 2 Joint undertaking, brings together clinical scientists from international…
The traditional classification of diabetes, mainly in type 1 and type 2 diabetes, has been challenged by studies from Scandinavia. In the current issue of The Lancet Diabetes & Endocrinology, researchers from DDZ together with colleagues from DZD and University of Lund published a cluster analysis of diabetes allowing for phenotyping into subgroups, which extended the findings by showing that…
SuperSonic Imagine announces that a multicenter retrospective study conducted in Europe and China, has confirmed the clinical utility of ShearWave Elastography in patients with chronic liver disease, the first results of which were presented at the International Liver Congress (ILC 2019). The objective of this study was to evaluate the diagnostic value of ShearWave Elastography (SWE) in the…
A review of evidence by researchers at King’s College London has found high levels of alcohol dependence among hospital inpatients. The researchers estimate one in five patients in the UK hospital system uses alcohol harmfully, and one in ten is alcohol dependent. Currently little is being done to screen routinely for alcohol dependence in hospitals, and services for patients with alcohol…
Non-alcoholic fatty liver disease (NAFLD) is a condition where fat accumulates in the liver and has become the most common liver disease worldwide. While NAFLD shows few or no symptoms at initial stages, it is a potentially serious disease which can progress to an inflammatory state called steatohepatitis (NASH), which can lead to liver cirrhosis and cancer. Fatty liver disease can be managed by…
Non-alcoholic fatty liver disease is among the most common chronic hepatic disorders in Western industrial countries and the rate is also rapidly rising in newly industrialized countries. Experts estimate that about 30 to 40 percent of the population worldwide develop this liver condition. In the United States, this disease is well on the way to becoming the most frequent indication for liver…
More than 100 million Americans have potentially deadly fatty liver disease and most do not even know it. Overeating and drinking excessive amounts of alcohol this holiday season could put someone with the disease on the fast track to liver failure. “There are no symptoms associated with fatty liver disease and no pain, so most people never get checked or treated for it and, over time, if it is…
A drug which has been used to treat liver disease for decades could help to restore cells damaged by Alzheimer's, a new study from the University of Sheffield has found. The pioneering study discovered the drug ursodeoxycholic acid (UDCA) improves mitochondrial dysfunction – which is known to be a causative factor for both sporadic and familial Alzheimer's disease.
Another piece in the puzzle that is non-alcoholic fatty liver disease has been solved by a University of Queensland researcher in a step towards developing treatments for a disease that affects about one in every five Australians. PhD student Laurence Britton has discovered a pivotal mechanism by which iron is able to make the liver more vulnerable to the injury and metabolic dysfunction that…
Scientists at the University of Delaware and the University of Illinois at Chicago have found a new way to kill liver cancer cells and inhibit tumor growth. First, they silence a key cellular enzyme, and then they add a powerful drug. They describe their methods in a new paper published in Nature Communications. This research could accelerate the development of new treatments for liver cancer,…
Patients with cirrhosis should be screened regularly for liver cancer, though few are – in part because busy physicians often don’t order the screening tests, said UT Southwestern oncologists. “The frequency of liver cancer is increasing rapidly in the U.S. and liver cancer-related mortality has nearly doubled over the past decade. The poor prognosis of the disease is largely driven by the…
In April 2016 CEUS received the USA’s FDA approval. This year‘s RSNA Samsung Symposium ‘Contrast-Enhanced Ultrasound (CEUS): Innovations and a Problem-Solving Tool in Clinical Practice’ provided an opportunity to take stock. For European Hospital, Professor André Clevert, Director of the Interdisciplinary Centre for Ultrasound at University Hospital Munich, Germany, describes the current…
Liver disease is widespread in Germany. It is, in fact, the most common cause of death in patients under the age of 40, with liver cirrhosis, which can develop into liver cancer, playing a major role here. These days, modern, comprehensive treatment concepts are unimaginable without interventional radiology, for liver cirrhosis as well as liver cancer. Prof. Dr. Christian Stroszczynski, Director…
Professor Dr Thomas Kröncke, Medical Director of Diagnostic and Interventional Radiology at Klinikum Augsburg, has been dealing with liver diseases for 17 years. Talking to European Hospital he explains which diseases the liver tends to mask and why fatty liver has become a public health issue.
From its earliest beginnings in 2006 to its most recent update this year, the Liver Imaging Reporting and Data System (LI-RADS) is helping radiologists deliver clearer and more consistent imaging reports to hepatologists and surgeons worldwide. "LI-RADS is the leading system for interpretation and reporting of liver imaging exams in adults with cirrhosis. It is also the first radiology…
A new study found that increased utilization of split liver transplantation could decrease the number of children who die awaiting liver transplantation without decreasing liver transplantation access for adult patients. “Among children listed for liver transplant in the United States, more than one in 10 infants and one in 20 older children die while waiting for a liver,” says Emily Perito,…
Approximately 10 percent of the general population take a proton pump inhibitor (PPI) drug to block stomach acid secretions and relieve symptoms of frequent heartburn, acid reflux and gastroesophageal reflux disease. That percentage can be as much as seven times higher for people with chronic liver disease. Researchers at University of California San Diego School of Medicine have discovered…
A Spanish team has, for the first time, successfully placed a pulmonary valve using catheterisation through the hepatic vein in a paediatric patient. Specialists believe this type of intervention could become an interesting alternative when traditional access points are not available.
German researches have linked the increased production of a certain enzyme in the liver to fatty liver and insulin resistance.
Non-alcoholic fatty liver disease (NAFLD) is one of the most frequent liver diseases worldwide and an estimated 20 million people in Germany are affected.